3,3-二氟己烷 | 358-68-9

• 分子结构分类: 有机化合物 - 有机卤素化合物 - 有机氟化物
• 中文名称: 3,3-二氟己烷
• 英文名称: 3,3-Difluorohexane
• 英文别名: 3,3-difluoro-hexane；3,3-Difluor-hexan；4,4-Difluorohexane；3.3-Difluoro-hexan
• CAS: 358-68-9
• 化学式: C₆H₁₂F₂
• 分子量: 122.158
• InChiKey: DDBCIMMPYTWLIO-UHFFFAOYSA-N

物化性质

• 熔点：
  -89.3 °C
• 沸点：
  86 °C(Press: 742 Torr)
• 密度：
  0.9024 g/cm3

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  8
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  3-己炔 在 poly-4-vinylpyridinium poly(hydrogen fluoride) (40/60) 作用下， 以 一氟三氯甲烷 为溶剂， 反应 72.0h， 以59%的产率得到3,3-二氟己烷
  参考文献：
  名称：

  Poly-4-vinylpyridinium Poly(Hydrogen Fluoride): A Solid Hydrogen Fluoride Equivalent Reagent

  摘要：

  聚-4-乙烯基吡啶聚（氟化氢）（PVPHF）是一种固态氟化氢等效试剂，含有35-60%的氟化氢（按重量计）。发现含有60%氟化氢的PVPHF是一种多功能的氟化试剂，可用于烯烃和炔烃的氟化氢化及溴氟化，醇的氟化以及其他氟化反应。低氟化氢含量的PVPHF（4-乙烯基吡啶单元1当量对应3当量氟化氢）在存在1,3-二溴-5,5-二甲基海因的情况下也被发现是一种有效的烯烃溴氟化试剂。氟磺酸修饰的PVPHF在第二醇氟化反应中显示出增强的反应活性。

  DOI：

  10.1055/s-1993-25924

文献信息

• [EN] 3-(1H-PYRROLO[3,2-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-C]PYRIDINES AND THERAPEUTIC USES THEREOF<br/>[FR] 3-(1H-PYRROLO[3,2-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-C]PYRIDINES ET LEURS UTILISATIONS THÉRAPEUTIQUES
  申请人：SAMUMED LLC

  公开号：WO2017023984A1

  公开（公告）日：2017-02-09

  6-Azaindazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of a 6-azaindazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.

  披露了用于治疗各种疾病和病理的6-氮杂吲唑化合物。更具体地，本公开涉及使用6-氮杂吲唑化合物或其类似物，治疗通过Wnt途径信号激活所特征化的疾病（例如癌症、异常细胞增殖、血管生成、纤维化疾病、骨骼或软骨疾病和骨关节炎），调节由Wnt途径信号介导的细胞事件，以及由于Wnt途径和/或一个或多个Wnt信号组分的突变或失调而导致的遗传疾病和神经病理状况/障碍/疾病。还提供了治疗与Wnt相关疾病状态的方法。
• [EN] MACROCYCLIC AND BICYCLIC INHIBITORS OF HEPATITIS C VIRUS<br/>[FR] INHIBITEURS MACROCYCLIQUES ET BICYCLIQUES DU VIRUS DE L'HÉPATITE C
  申请人：GILEAD SCIENCES INC

  公开号：WO2014145095A1

  公开（公告）日：2014-09-18

  Compounds of formula (I):or pharmaceutically acceptable salts thereof, wherein the various substituents are defined herein, methods of using said compounds, and pharmaceutical compositions containing said compounds.

  式(I)的化合物或其药用可接受的盐，其中各种取代基在此定义，使用所述化合物的方法，以及含有所述化合物的药物组合物。
• [EN] 3-(1H-PYRROLO[2,3-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-C]PYRIDINES AND THERAPEUTIC USES THEREOF<br/>[FR] 3-(1H-PYRROLO[2,3-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-C]PYRIDINES ET LEUS UTILISATIONS THÉRAPEUTIQUES
  申请人：SAMUMED LLC

  公开号：WO2017023975A1

  公开（公告）日：2017-02-09

  6-Azaindazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of a 6-azaindazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.

  披露了用于治疗各种疾病和病理的6-氮杂吲唑化合物。更具体地说，本公开涉及使用6-氮杂吲唑化合物或其类似物，用于治疗由Wnt途径信号激活（例如，癌症、异常细胞增殖、血管生成、纤维化疾病、骨骼或软骨疾病和骨关节炎）引起的疾病，调节由Wnt途径信号介导的细胞事件，以及由于Wnt途径及其一个或多个Wnt信号成分的突变或失调引起的遗传性疾病和神经病学状况/疾病/疾病。还提供了治疗Wnt相关疾病状态的方法。
• [EN] 3-(1H-PYRROLO[3,2-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF<br/>[FR] 3-(1H-PYRROLO[3,2-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-B]PYRIDINES ET LEURS UTILISATIONS THÉRAPEUTIQUES
  申请人：SAMUMED LLC

  公开号：WO2017023987A1

  公开（公告）日：2017-02-09

  7-Azaindazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of a 7-azaindazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.

  7-氮杂吲唑化合物用于治疗各种疾病和病理已被披露。更具体地，本公开涉及使用7-氮杂吲唑化合物或其类似物，治疗通过Wnt途径信号激活所特征化的疾病（例如，癌症，异常细胞增殖，血管生成，纤维化疾病，骨骼或软骨疾病和骨关节炎），调节由Wnt途径信号介导的细胞事件，以及由于Wnt途径和/或一个或多个Wnt信号组分的突变或失调而导致的遗传疾病和神经病理状况/障碍/疾病。还提供了治疗与Wnt相关疾病状态的方法。
• [EN] 3-(1H-PYRROLO[3,2-C]PYRIDIN-2-YL)-1H-INDAZOLES AND THERAPEUTIC USES THEREOF<br/>[FR] 3-(1H-PYRROLO[3,2-C]PYRIDIN-2-YL)-1H-INDAZOLES ET LEURS UTILISATIONS THÉRAPEUTIQUES
  申请人：SAMUMED LLC

  公开号：WO2017024010A1

  公开（公告）日：2017-02-09

  Indazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of an indazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.

  披露了用于治疗各种疾病和病理的吲唑化合物。更具体地，本公开涉及使用吲唑化合物或其类似物治疗由Wnt途径信号激活所特征的疾病（例如癌症、异常细胞增殖、血管生成、纤维化疾病、骨骼或软骨疾病和骨关节炎），调节由Wnt途径信号介导的细胞事件，以及由于Wnt途径的突变或失调和/或一个或多个Wnt信号组分的遗传疾病和神经病理状况/障碍/疾病的遗传疾病和神经病理状况/障碍/疾病。还提供了治疗与Wnt相关疾病状态的方法。